Last reviewed · How we verify
NCT03937349
Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
trial in Secondary Hyperparathyroidism in 63 participants. Completed in 18 January 2024.
18 January 2024
Quick facts
| Lead sponsor | Saint Petersburg State University, Russia |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 14 May 2019 |
| Primary completion | 18 January 2024 |
| Estimated completion | 18 January 2024 |
| Sites | 1 location across Russia |
Conditions studied
- Secondary Hyperparathyroidism — all drugs for Secondary Hyperparathyroidism →
- Chronic Kidney Disease Mineral and Bone Disorder — all drugs for Chronic Kidney Disease Mineral and Bone Disorder →
- Vascular Calcification — all drugs for Vascular Calcification →
- Dialysis — all drugs for Dialysis →
Sponsor
Saint Petersburg State University, Russia
Who can join
18 and older, any sex, with Secondary Hyperparathyroidism or Chronic Kidney Disease Mineral and Bone Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cohort study aimed to evaluate change of cardiovascular calcification after parathyroidectomy in patients with end-stage renal disease on dialysis compared with control group on conservative treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Vascular calcification: from the perspective of crosstalk.
Yang S, Zeng Z, Yuan Q, Chen Q, et al · · 2023 · cited 13× · PMID 37851172 · DOI 10.1186/s43556-023-00146-y
Verify or expand the search:
- PubMed search for NCT03937349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Secondary Hyperparathyroidism
Currently open trials in the same condition.
- NCT06130683 — Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism · active not recruiting
- NCT05880914 — Precision Medicine Approaches to Renal Osteodystrophy · recruiting
- NCT03969329 — A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis · Phase 3 · recruiting
- NCT03633708 — A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemo · Phase 3 · recruiting
Other Saint Petersburg State University, Russia trials
Trials by the same sponsor.
- NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
- NCT07185334 — Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating · NA · active not recruiting
- NCT07106112 — Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy · NA · recruiting
- NCT06654401 — Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm · NA · recruiting
- NCT06626711 — Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells · EARLY_PHASE1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03937349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Saint Petersburg State University, Russia
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03937349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing